Dmytro Havrylyuk

Dmytro Havrylyuk is a Senior Research Scholar in the Department of Chemistry at North Carolina State University, specializing in the development of photoactivated and traditional chemotherapeutic agents through innovative inorganic and organometallic chemistry approaches.

His educational qualifications include:

• Ph.D. in Pharmaceutical Chemistry and Pharmacology from Danylo Halytsky Lviv National Medical University, Ukraine (2007)
• B.S. in Pharmacy from Danylo Halytsky Lviv National Medical University, Ukraine (2003)

Havrylyuk's research centers on photoactivated chemotherapy, ruthenium-based anticancer agents, and light-controlled enzyme modulation. He pioneers ruthenium(II) photocages for red-light activation in deep tissues, hypoxia-selective cytotoxic complexes, and PROTACs with spatiotemporal precision. His work bridges synthetic chemistry with cancer biology to overcome limitations of conventional therapies through targeted bioenergetic disruption and controlled drug release.

Analysis of his 15 most recent publications (2018-2025) reveals three dominant trajectories: (1) Engineering ruthenium complexes for hypoxic tumor targeting and red-light activation, (2) Developing dual-action agents combining photoactivation with cytochrome P450 inhibition, and (3) Elucidating metabolic impacts of photoactivated therapies on ATP dynamics and ribosome biogenesis. This work establishes foundational principles for next-generation metal-based photo-pharmacology.

No scientific awards are documented in available sources.

As a research scholar, Havrylyuk leads independent projects within the Glazer Research Group while collaborating with oncology and pharmacology teams. His grant-funded work focuses on synthesizing metal complexes and evaluating their biological mechanisms, though specific funding details remain unreported. He mentors junior researchers in synthetic techniques and biological screening protocols without formal student advisement roles.

Havrylyuk operates within the Glazer Research Group, a multidisciplinary team specializing in bioinorganic photochemistry. The group employs advanced spectroscopy, cellular assays, and animal models to develop light-activated therapeutics with clinical translation potential, particularly for treatment-resistant cancers.